The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in patients with untreated non–small cell lung cancer. Brigatinib yielded a longer progression-free survival, a higher objective response rate, and greater effectiveness against brain metastases—and was less detrimental to patients' quality of life.

©2019 American Association for Cancer Research.
2019
American Association for Cancer Research.
You do not currently have access to this content.